key: cord-0988769-gk3wc2ov authors: Bacaksız, Ferhat; Ebik, Berat; Ekin, Nazım; Kılıc, Jihat title: Pancreatic damage in COVID‐19: Why? How? date: 2021-08-06 journal: Int J Clin Pract DOI: 10.1111/ijcp.14692 sha: 63e67ddbc64c15a43c400a2afd46b0cb0513fe50 doc_id: 988769 cord_uid: gk3wc2ov OBJECT: We aimed to evaluate the elevation of amylase and lipase enzymes in coronavirus disease 2019 (COVID‐19) patients and their relationship with the severity of COVID‐19. METHOD: In this study, 1378 patients with COVID‐19 infection were included. Relation of elevated amylase and lipase levels and comorbidities with the severity of COVID‐19 was analysed. The effects of haemodynamic parameters and organ failure on pancreatic enzymes and their relations with prognosis were statistically analysed. RESULTS: The 1378 patients comprised of 700 (51.8%) men and 678 (%49.2) women. Of all patients, 687 (49.9%) had mild and 691 (50.1%) patients had severe COVID‐19 infection. Amylase elevation at different levels occurred in 316 (%23) out of 1378 patients. In these patients, the amylase levels increased one to three times in 261 and three times in 55 patients. Pancreatitis was detected in only six (%1.89) of these patients according to the Atlanta criteria. According to univariate and multivariate analyses, elevated amylase levels were significantly associated with the severity of COVID‐19 (odds ratio [OR]: 4.37; P < .001). Moreover, diabetes mellitus (DM; OR: 1.82; P = .001), kidney failure (OR: 5.18; P < .001), liver damage (OR: 6.63; P < .001), hypotension (OR: 6.86; P < .001) and sepsis (OR: 6.20; P = .008) were found to be associated with mortality from COVID‐19. CONCLUSION: Elevated pancreatic enzyme levels in COVID‐19 infections are related to the severity of COVID‐19 infection and haemodynamic instability. In a similar way to other organs, the pancreas can be affected by severe COVID‐19 infection. The 1378 patients comprised of 700 (51.8%) men and 678 (%49.2) women. The prevalence of kidney failure, DM, ischaemic hepatitis and sepsis was significantly higher in patients with severe COVID-19 compared with patients with mild disease. Moreover, amylase and lipase levels were also higher in patients with severe COVID-19 (Table 1) . Amylase elevation at different levels occurred in 316 (%23) out of 1378 patients. In these patients, the amylase levels increased one to three times in 261 and three times in 55 patients. Pancreatitis was detected in only six (%1.89) of these patients according to the Atlanta criteria. Amylase and lipase elevation was found to be related to the severity of COVID-19 infection in the remaining patients. The development of DM, kidney failure, hypotension and ischaemic hepatitis was found to be related to mortality from COVID-19 infection. However, there was no relationship between lymphopenia and elevated amylase levels (Table 2) . On the other hand, patients older than 65 years were more likely to have (1.89 times) elevated increased enzyme levels. The prevalence of elevated amylase was 2.04 times higher in men than that in women. Hypotension (odds ratio [OR]: 6.63), sepsis (OR: 6.20), ischaemia-related liver damage (OR: 6.63) and renal failure (OR: 5.18) were found to be significantly associated with pancreatic enzyme levels (Table 3) . A very strong positive correlation was found between amylase and lipase levels in all patients (r: .828, P < .001), which implicates that the increased amylase in COVID-19 patients is caused by the pancreas. A weak correlation was found between amylase level and What's known • It has been suggested that COVID-19 can cause pancreatic damage. • There are a limited number of studies related to the possibility of an increase in the level of pancreatic enzymes in COVID-19 patients. • COVID-19 does not directly cause pancreatic damage. • Pancreatic enzyme elevation in patients with COVID-19 develops in the advanced stages of the disease caused by multiple organ dysfunction and shock. age or gender. Likewise, a weak but statistically significant correlation was found between amylase level and DM. A strong correlation was detected between the amylase level and the severity of COVID-19. Additionally, the presence of liver damage, renal failure, hypotension and multiple organ dysfunction syndrome (MODS) in these patients was moderately correlated with amylase level (Figure 1 ). We found that 23% of patients with COVID-19 infection had pancreatic enzyme elevations, and we also detected a relationship between pancreatic enzyme elevation and the severity of COVID-19 infection, haemodynamic instability and MODS. A study investigating the relationship between COVID-19 infection and pancreas reported pancreatic damage in 1%-2% and 17% of patients with mild and severe infection, respectively. The authors suggested that pancreatic damage can be exacerbated by systemic inflammation. [14] [15] [16] [17] Amylase and lipase elevation suggestive of pancreatic damage has been reported in 8.5%-17.3% of patients with COVID-19. Moreover, higher enzyme levels have been reported in severe COVID-19 patients. [14] [15] [16] [17] Likewise, in two previous autopsy studies, five of 11 (45.5%) and two of eight (25%) cases were detected with focal pancreatitis with haemorrhagic and necrotic changes in the pancreas. These changes had no clinical manifestations and were attributed to ischaemia and end-organ damage. 18, 19 In the light of our data, we consider that pancreatic damage is the most important cause of amylase and lipase elevations. The exact pathophysiology of pancreatic damage remains unclear, while the most widely accepted hypothesis points to pancreatic ischaemia. [20] [21] [22] If septicaemia progresses towards septic shock, not only in COVID-19 but also in other infections, the resulting hypotension and vasodilation reduce blood flow to organs. To protect blood flow to vital organs such as the brain and heart, blood flow to the celiac, superior and inferior mesenteric arteries are reduced as a part of the protective mechanism. Afterwards, this is followed by renal and iliac arteries. This is the neurohormonal mechanism protecting vital organs. Gastrointestinal system is the target organ of shock and hypotension. As a result, the blood flow to the liver, pancreas and the entire gastrointestinal system is reduced, thereby causing symptoms such as nausea, vomiting, distension, ileus, or diseases such as ischaemic hepatitis. Pancreas is supplied well by pancreatic arteries that stem from the splenic, gastroduodenal and superior mesenteric arteries. Amylase, lipase, aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) are released into the bloodstream caused by the ischaemia resulting from decreased blood flow to the pancreas. 23 This damage is mainly caused by haemodynamic deterioration, not by the virus itself. Similarly, in our study, elevated amylase and lipase levels were found to be associated with haemodynamic parameters and hypotension. Although increased amylase and lipase levels might have clinical importance, it seems highly unlikely to use these parameters as prognostic indicators in clinical practice, mainly because enzyme elevation occurs during the intensive care period when the disease is severe and requires mechanical ventilation. At this stage, most patients have single or multiple organ failure and require vasopressor support. In conclusion, although ACE2 receptors are expressed highly in pancreatic tissue, pancreatic enzyme elevations occurring in Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes Combined serum amylase and lipase determinations for diagnosis of suspected Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus Clinical management of COVID-19. WHO interim guidance. COVID-19: Clinical care Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis COVID-19 and liver clinical practice guidelines: drug-induced liver injury The RIFLE criteria and mortality in acute kidney injury: a systematic review Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence Lipase elevation in patients with COVID-19 Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia Marked elevation of lipase in COVID-19 disease: a cohort study Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a postmortem study Effect of PGE1 on altered distribution of regional blood flows in hyperdynamic sepsis Dynamic study of the distribution of microcirculatory blood flow in multiple splanchnic organs in septic shock Pancreatic injury in patients with septic shock: a literature review Pancreatic blood flow with special emphasis on blood perfusion of the islets of Langerhans COVID-19 infection presenting as pancreatitis in a pregnant woman: a case report Recurrent acute pancreatitis in a patient with COVID-19 infection Pancreatic damage in COVID-19: Why? How?